AVEO Pharmaceuticals, Inc.
ANTI-ERBB3 ANTIBODIES

Last updated:

Abstract:

Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.

Status:
Application
Type:

Utility

Filling date:

29 Oct 2019

Issue date:

24 Sep 2020